---
layout: default
title: Ascorbic Acid
parent: 僅模型預測 (L5)
nav_order: 35
evidence_level: L5
indication_count: 10
---

# Ascorbic Acid
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ascorbic Acid: From Vitamin C Deficiency to Non-Syndromic Esophageal Malformation

## One-Sentence Summary

Ascorbic acid (Vitamin C, DB00126) is an essential micronutrient whose therapeutic use is classically established for treating and preventing vitamin C deficiency (scurvy), acting as a cofactor for collagen synthesis enzymes and as a broad antioxidant. The TxGNN model predicts it may be effective for **Non-Syndromic Esophageal Malformation**, with **0 clinical trials** and **0 publications** currently supporting this specific direction. Despite an exceptionally high prediction score (99.96%), this is assessed as a likely knowledge-graph propagation artifact with no established mechanistic basis.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No approved indication on record in New Zealand (ascorbic acid is classically indicated for vitamin C deficiency / scurvy) |
| Predicted New Indication | Non-Syndromic Esophageal Malformation |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 — Model prediction only, no supporting studies |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, ascorbic acid (Vitamin C) is a water-soluble essential nutrient that serves as a cofactor for prolyl and lysyl hydroxylases in collagen biosynthesis, regenerates oxidized vitamin E, promotes non-heme iron absorption, and fulfills broad antioxidant roles across multiple organ systems.

Non-syndromic esophageal malformation refers to structural congenital anomalies of the esophagus — such as esophageal atresia or tracheo-esophageal fistula — occurring in isolation, without a recognizable associated syndrome. These are embryological defects arising during organogenesis, not diseases amenable to pharmacological correction after birth. Although ascorbic acid is required for collagen cross-linking and connective tissue maturation, there is no established mechanism by which vitamin C supplementation could prevent or reverse a structural congenital defect of the esophagus.

The TxGNN model assigned this indication a prediction score of 99.96%, most likely due to broad disease-node similarity propagation through esophageal disease clusters in the knowledge graph rather than any specific molecular signal. The pipeline's own mechanistic assessment acknowledges the absence of any known direct role for ascorbic acid in esophageal morphogenesis, classifying this as a probable false-positive driven by graph topology rather than biological plausibility.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No clinical trials, published literature, or plausible mechanistic hypothesis currently supports the use of ascorbic acid for non-syndromic esophageal malformation. A TxGNN L5 prediction in isolation — particularly one assessed as a likely graph propagation artifact — is insufficient to justify further investigational investment.

**To proceed, the following is needed:**
- Establish a biologically plausible hypothesis connecting ascorbic acid to esophageal embryogenesis or post-surgical malformation repair (e.g., collagen-dependent anastomotic healing after surgical correction)
- Conduct a focused literature review on vitamin C status in neonates undergoing esophageal atresia repair
- Retrieve DrugBank mechanism of action data to identify any molecular targets expressed in esophageal tissue
- Obtain package insert safety data (key warnings, contraindications, drug interactions) before any clinical hypothesis generation
- Request expert consultation to determine whether the TxGNN knowledge graph node for "non-syndromic esophageal malformation" correctly represents the disease biology or contains modelling artefacts
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

